Instrumental variables


Britain can become a world innovator in healthcare technology following Brexit. The new report by Mark Lutter argues that Britain should streamline the approvals process for new medicines and health technologies, as well as allowing the use in Britain of medical products already approved by regulators in other countries with safe track records of medical regulation.

By recognising decisions on drugs and medical devices approved by sensible regulators overseas would give Brits access to an increased number of safe and effective drugs, while at the same time cutting costs. Brexit is an opportunity for Britain to overhaul and streamline its regulatory regime, the UK must seize this opportunity for regulatory reform for the health of its citizens.

Read Full Report

Explore our reports

  • Reset
Advanced search